Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Alcon President & CEO: Cary Rayment plans to build Alcon's international surgical and pharmaceutical businesses in Asia after assuming the joint position Oct. 1. He will seek further expansion into Japan, the firm's second largest market behind the U.S., as well as China, Korea and India. Rayment, 57, will replace Tim Sear, 67, who has been with Alcon 34 years and saw the firm through its 2002 initial public offering. In 2001, Rayment became senior-VP, directing cross-divisional efforts for surgical, pharmaceutical and consumer groups in the U.S. In January, he took responsibility for Alcon Japan. Rayment has been with Alcon since it acquired CooperVision Surgical in 1989. Kevin Buehler, 47, a 20-year Alcon veteran and VP-operations, Latin America, Canada and the Far East, will replace Rayment...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel